Discontinuation report HUMIRA
| Report ID | 119141 |
| Drug Identification Number | 02258595 |
| Brand name | HUMIRA VIAL |
| Common or Proper name | HUMIRA (ADALIMUMAB) VIAL |
| Company Name | ABBVIE CORPORATION |
| Market Status | MARKETED |
| Active Ingredient(s) | ADALIMUMAB |
| Strength(s) | 40MG |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Packaging size | 2 x 0.8mL vial (40mg/0.8mL) |
| ATC code | L04AB |
| ATC description | IMMUNOSUPPRESSANTS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2020-11-02 |
| Actual discontinuation date | 2020-11-18 |
| Remaining supply date | 2020-11-02 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | Last HUMIRA vial lot available on market expires on June 2021. Per AbbVie’s return policy, the HUMIRA vial is a non-eligible product for credit. |
| Company comments | The HUMIRA 40mg vial will be phased out by November 2nd 2020. AbbVie has now introduced the new HUMIRA 20 mg pre-filled syringe for pediatric patients prescribed HUMIRA 20mg. HUMIRA 40mg in PEN and pre-filled syringe are still available for pediatric patients prescribed HUMIRA 40mg. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 8401 TRANS-CANADA HIGHWAY SAINT-LAURENT, QUEBEC CANADA H4S 1Z1 |
| Company contact information | Should you require any additional information, please contact our Customer Service Department at 1-888-704-8270. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v8 | 2020-11-19 | French | Compare |
| v7 | 2020-11-19 | English | Compare |
| v6 | 2020-10-28 | French | Compare |
| v5 | 2020-10-28 | English | Compare |
| v4 | 2020-06-29 | English | Compare |
| v3 | 2020-06-29 | English | Compare |
| v2 | 2020-06-29 | French | Compare |
| v1 | 2020-06-29 | English | Compare |
Showing 1 to 8 of 8